BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Scientists find evidence that an asteroid contains tryptophan - 2Improving as a Cook: Culinary Experiences in the Kitchen
- 3Overlooked infertility care should be part of national health services, says WHO
- 410 Setting up camp Shelters That Offer Both Excellence and Isolation
- 5She was moments away from giving birth. The hospital discharged her
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- Opening Potential: Self-awareness and Long lasting Learning
- Scientists discover black hole flare with the light of 10 trillion suns
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- Pick Your Favored method of transportation
- Well known Worldwide Caf\u00e9s to Experience
- Find Successful Magnificence Items for Sparkling Skin
- 2024 Eurovision winner Nemo returns trophy over Israel's participation
